Companies›Healthcare›Healthcare›Pharmaceuticals & Biotechnology

Shyama Computronics and Servic

Healthcare › Pharmaceuticals & Biotechnology
₹3.66
at close · 26 Oct 2026
▲ 0.00 (+0.00%)

Latest filings

  1. RTA certificate under SEBI Regulation 74(5) filed with BSE for Sept 2026 quarter · Compliance
  2. Clarification on alleged delay in AGM proceedings filing · Regulatory & Legal
  3. Trading window closes Oct 1 for Q2 FY26 results · Compliance
All filings ↓
Ask Nexa about Shyama Computronics and Servic

Snapshot

What the business is, and whether it's a good one at a fair price.

A Pharmaceuticals & Biotechnology company listed on BSE, reporting revenue of ₹0 Cr over the trailing twelve months.

Market Cap
₹4 Cr
P / E (TTM)
30.5×
EV / EBITDA
25.2×
Div Yield
—
Growth
13.3%▲
Revenue 5y CAGR
PAT +7.6% · EBITDA -8.1%
Quality
1.5%·
ROCE (5y median)
ROE 1.1% (5y median) · margin 55.1%
Leverage
0.00·
Debt / Equity · low
Net cash ₹0.01 Cr
Revenue FY21→FY26
1.9×▲
Margin −11.9 pts
₹0 Cr → ₹0 Cr
Cash conversion
-5.24×▼
Operating cash ÷ profit · 5 yrs
₹-3 Cr on ₹1 Cr
Moves on a normal day
4.17%·
Median daily move
Last 123 sessions · the yardstick for filing-day moves
Where it sits among 185 Pharmaceuticals peersBar = share of peers beaten · tick = industry median · latest reported figures
P/E (TTM)#80/158
P/B#6/163
ROCE#144/183
ROE#136/166
Debt / Equity#1/166
EBITDA margin#116/165
Revenue growth#99/161
Profit growth#133/158

Scorecard

Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice

Strengths
Revenue compounding 13% a year over 5 years
No borrowings on the balance sheet
lower than 79% of its 166 Pharmaceuticals peers
Concerns
Returns on capital 1.5% (5-year median)
#144 of 183 in Pharmaceuticals on the latest reported figures
Over 5 years it reported ₹0.51 Cr of profit and an operating cash outflow of ₹2.66 Cr — -5.24×
Less than 60p of every ₹1 of profit arrived as cash

Charts

How has the market priced it — with filings on the timeline?

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Peers

How does it stack up on valuation, returns and growth?

Loading peers…

Financials

Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.

Loading financials…

Ownership

Who owns it — and is the promoter stake clean?

Loading shareholding…

Sign up to see the full company file

Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.

Common questions

Answered from Shyama Computronics and Servic's filed financials and exchange disclosures

What does Shyama Computronics and Servic do?

Shyama Computronics and Servic is a Pharmaceuticals & Biotechnology company listed on BSE.

Is Shyama Computronics and Servic profitable?

Yes. Over the trailing twelve months Shyama Computronics and Servic reported a net profit of ₹0.11 Cr on revenue of ₹0.29 Cr.

Does Shyama Computronics and Servic pay a dividend?

Not in the latest reported year — Shyama Computronics and Servic's dividend payout for FY26 was nil.

Is Shyama Computronics and Servic debt-free?

Yes. It reported no borrowings on its 31 Mar 2026 balance sheet, and ₹0.01 Cr of cash.

Is Shyama Computronics and Servic expensive compared with its peers?

On trailing P/E, Shyama Computronics and Servic ranks 80 of 158 in Pharmaceuticals — cheaper than 50% of them, against an industry median of 30.1×. This is a position, not a valuation judgement.

How much does the Shyama Computronics and Servic share price move in a day?

On a typical session Shyama Computronics and Servic moves 4.17% — that is the median absolute close-to-close move across its last 123 trading days. MarketPing measures each filing's price reaction against it.

Where can I track Shyama Computronics and Servic's announcements?

Every NSE and BSE filing by Shyama Computronics and Servic appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.

Figures are as last reported and may lag the latest filing. Not investment advice.